Innovative medicine : basic research and development /

Saved in:
Bibliographic Details
Meeting name:Uehara Memorial Foundation Symposium (2014 : Tokyo, Japan)
Imprint:Tokyo : SpringerOpen, [2015]
©2015
Description:1 online resource (ix, 339 pages) : illustrations
Language:English
Series:Online access with purchase: Springer.
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11097125
Hidden Bibliographic Details
Other authors / contributors:Nakao, Kazuwa, 1948- editor.
Minato, Nagahiro, editor.
Uemoto, Shinji, editor.
ISBN:9784431556510
4431556516
9784431556503
4431556508
Digital file characteristics:text file PDF
Notes:Proceedings from the Uehara Memorial Foundation Symposium held in Tokyo, 15-17 June, 2014.
Includes bibliographical references.
Online resource; title from PDF title page (SpringerLink, viewed April 19, 2016).
Summary:"This book is devoted to innovative medicine, comprising the proceedings of the Uehara Memorial Foundation Symposium 2014. It remains extremely rare for the findings of basic research to be developed into clinical applications, and it takes a long time for the process to be achieved. The task of advancing the development of basic research into clinical reality lies with translational science, yet the field seems to struggle to find a way to move forward. To create innovative medical technology, many steps need to be taken: development and analysis of optimal animal models of human diseases, elucidation of genomic and epidemiological data, and establishment of proof of concept. There is also considerable demand for progress in drug research, new surgical procedures, and new clinical devices and equipment. While the original research target may be rare diseases, it is also important to apply those findings more broadly to common diseases. The book covers a wide range of topics and is organized into three complementary parts. The first part is basic research for innovative medicine, the second is translational research for innovative medicine, and the third is new technology for innovative medicine. This book helps to understand innovative medicine and to make progress in its realization"--Publisher's description.
Other form:Print version: Innovative medicine. Tokyo : Springer, ©2015 4431556508
Standard no.:10.1007/978-4-431-55651-0
Table of Contents:
  • Part I: Basic research for innovative medicine. Diverting Glycolysis to Combat Oxidative Stress
  • Metabolic Regulation by Nuclear Receptors
  • Fighting Fire with Fire in Cancer
  • Linear Polyubiquitination: a Crucial Regulator of NF-kB Activation
  • VCP, a major ATPase in the cells, as a novel drug target for currently incurable disorders
  • Roles of E-cadherin in hepatocarcinogenesis
  • The hippo signaling pathway: a candidate new drug target for malignant tumors
  • Inhibitory immunoreceptors on mast cells in allergy and inflammation
  • Doxycycline-inducible Autoimmune Blistering Skin Disease Model
  • T-cell Senescence and Autoimmunity
  • Part II: Translational research for innovative medicine. IL-6: A new era for the treatment of autoimmune inflammatory diseases
  • Pathogenesis of Non-alcoholic Steatohepatitis and Its Potential Therapeutic Strategies
  • Multifaceted translational approach of major mental illness
  • Translational research of leptin in lipodystrophy and its related diseases
  • Translational research of the activation of the C-type natriuretic peptide (CNP)-guanylyl cyclase-B pathway for skeletal dysplasia
  • Clarity and challenges in tissue fibrosis
  • TRP channels: their function and potentiality as drug targets
  • Autophagic Cell Death and Cancer Chemotherapeutics
  • Adrenomedullin as a potential therapeutic agent for refractory ulcerative colitis
  • RNA activation
  • Part III: New technology for innovative medicine. Cardiac reprogramming for heart repair
  • Development of a new in vivo optical probe for biological diagnosis and therapy
  • Introduction of mesenchymal stem cells for liver surgery (hepatectomy and transplantation)
  • Synaptic and axonal plasticity induction in the human cerebral cortex
  • TIM-3 is a novel therapeutic target for eradicating acute myelogenous leukemia stem cells
  • TGF-beta LAP degradation products, a novel biomarker and promising therapeutic target for liver fibrogenesis
  • Cell-based regenerative therapy for liver disease.